Long-term pneumococcal antibody follow-up after Prevenar in prior Wyeth study 0887X-101518 participants

Phase 4 trial of pneumococcal 7-valent conjugate vaccine in pneumococcal disease (3 arms), sponsored by Pfizer. Primary endpoints: Geometric Mean Concentration for serotype-specific pneumococcal IgG antibody, 36 months after the toddler dose and Comparison of antibody levels between prior Prevenar recipients and non-recipients.